JP2010511694A - 新規なタンパク質キナーゼ修飾因子および治療におけるその使用 - Google Patents

新規なタンパク質キナーゼ修飾因子および治療におけるその使用 Download PDF

Info

Publication number
JP2010511694A
JP2010511694A JP2009539869A JP2009539869A JP2010511694A JP 2010511694 A JP2010511694 A JP 2010511694A JP 2009539869 A JP2009539869 A JP 2009539869A JP 2009539869 A JP2009539869 A JP 2009539869A JP 2010511694 A JP2010511694 A JP 2010511694A
Authority
JP
Japan
Prior art keywords
compound
halogen
compound according
compounds
ptk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009539869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511694A5 (https=
Inventor
アダス ルーヴェニ
アレクサンダー レヴィツキ
リラハ シュタイナー
レヴィタル サッソン
アイリス ベン−デビッド
アヴィ ヴァイスベルク
Original Assignee
ノヴォタイア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォタイア セラピューティクス リミテッド filed Critical ノヴォタイア セラピューティクス リミテッド
Publication of JP2010511694A publication Critical patent/JP2010511694A/ja
Publication of JP2010511694A5 publication Critical patent/JP2010511694A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2009539869A 2006-12-04 2007-12-04 新規なタンパク質キナーゼ修飾因子および治療におけるその使用 Pending JP2010511694A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87251106P 2006-12-04 2006-12-04
PCT/IL2007/001494 WO2008068751A1 (en) 2006-12-04 2007-12-04 Novel protein kinase modulators and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2010511694A true JP2010511694A (ja) 2010-04-15
JP2010511694A5 JP2010511694A5 (https=) 2012-02-02

Family

ID=39111493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539869A Pending JP2010511694A (ja) 2006-12-04 2007-12-04 新規なタンパク質キナーゼ修飾因子および治療におけるその使用

Country Status (8)

Country Link
US (1) US8058309B2 (https=)
EP (1) EP2125712B1 (https=)
JP (1) JP2010511694A (https=)
CN (1) CN101652345A (https=)
AU (1) AU2007330333A1 (https=)
BR (1) BRPI0719708A2 (https=)
CA (1) CA2671632A1 (https=)
WO (1) WO2008068751A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512937A (ja) * 2017-11-16 2021-05-20 ティルノーヴォ リミテッド がん治療のためのｉｒｓ／ｓｔａｔ３デュアルモジュレーターと抗ｐｄ−１／ｐｄ−ｌ１抗体との組み合わせ

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285774B1 (en) 2008-06-05 2015-02-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Novel modulators of protein kinase signaling
EP2658847B1 (en) * 2010-12-27 2015-12-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. 2-(2-phenylethenyl)-1,3-benzothiazine derivatives useful for the treatment of cancer
WO2012117396A1 (en) 2011-03-01 2012-09-07 Novotyr Therapeutics Ltd Tyrphostin derivative in combination with cytotoxic compounds for treating cancer
US9770454B2 (en) 2013-07-14 2017-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
CN112353938A (zh) 2015-02-05 2021-02-12 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN115466205B (zh) * 2021-11-04 2023-10-24 特尔诺沃有限公司 分离的3-（2-溴-3,4-二羟基-苯基）-n-（3,4,5-三羟基-苄基）-硫代丙烯酰胺的反式异构体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
JP2005513100A (ja) * 2001-12-10 2005-05-12 デュ，ヤンシェン 神経変性疾患および心臓血管疾患の治療
JP2005516983A (ja) * 2001-06-14 2005-06-09 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム チルホスチン化合物を用いた骨髄機能非除去的な寛容原性処置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
PT2527315E (pt) * 2002-05-31 2014-06-24 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
JP2005516983A (ja) * 2001-06-14 2005-06-09 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム チルホスチン化合物を用いた骨髄機能非除去的な寛容原性処置
JP2005513100A (ja) * 2001-12-10 2005-05-12 デュ，ヤンシェン 神経変性疾患および心臓血管疾患の治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013009742; Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３４，　Ｎｏ．６, ｐ．１８９６-１９０７　（１９９１）． *
JPN6013009744; Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３４，　Ｎｏ．４６, ｐ．１５１１１-１５１２２　（１９９５）． *
JPN6013009747; Ｊｏｕｒｎａｌ　ｏｆ　Ｍｏｌｅｃｕｌａｒ　Ｓｔｒｕｃｔｕｒｅ：　Ｔｈｅｏｃｈｅｍ Ｖｏｌ．５２９, ｐ．２７３-２８２　（２０００）． *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512937A (ja) * 2017-11-16 2021-05-20 ティルノーヴォ リミテッド がん治療のためのｉｒｓ／ｓｔａｔ３デュアルモジュレーターと抗ｐｄ−１／ｐｄ−ｌ１抗体との組み合わせ
JP7236163B2 (ja) 2017-11-16 2023-03-09 ティルノーヴォ リミテッド がん治療のためのｉｒｓ／ｓｔａｔ３デュアルモジュレーターと抗ｐｄ－１／ｐｄ－ｌ１抗体との組み合わせ

Also Published As

Publication number Publication date
US20100056635A1 (en) 2010-03-04
EP2125712A1 (en) 2009-12-02
AU2007330333A1 (en) 2008-06-12
US8058309B2 (en) 2011-11-15
WO2008068751A1 (en) 2008-06-12
BRPI0719708A2 (pt) 2014-02-18
CA2671632A1 (en) 2008-06-12
EP2125712B1 (en) 2014-07-23
CN101652345A (zh) 2010-02-17

Similar Documents

Publication Publication Date Title
JP2010511694A (ja) 新規なタンパク質キナーゼ修飾因子および治療におけるその使用
KR102618773B1 (ko) 디아릴 거대환형 화합물을 수반하는 병용 요법
JP7394768B2 (ja) キナーゼ阻害剤としての環状イミノピリミジン誘導体
HRP20030118A2 (en) Selective androgen receptor modulators and methods of use thereof
TW201728583A (zh) 氨基噻唑化合物及其用途
SK6282001A3 (en) N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors
NZ572231A (en) Inhibitors of the task-1 and task-3 ion channel
EP2285774B1 (en) Novel modulators of protein kinase signaling
KR20180100373A (ko) 아스코클로린 유도체 및 ampk 활성제로서의 이의 용도
WO2004013091A2 (en) 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
CN110831596A (zh) 作为蛋白激酶抑制剂的氨基噻唑化合物
JPWO2006104161A1 (ja) ｃ−Ｍｅｔ自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体
JP2022031509A (ja) アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤
WO2015021894A1 (zh) 新型羟肟酸衍生物及其医疗应用
KR102267662B1 (ko) 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US20120083528A1 (en) Novel protein kinase modulators and therapeutic uses thereof
KR20170108150A (ko) 항암 화합물
US9073880B2 (en) 2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer
US20050143430A1 (en) Catechol bioisosteres
JP2024515727A (ja) チューブリン重合阻害剤としての代謝的に安定なピリミジニルジヒドロキノキサリノン
EP2388247B1 (en) Histone deacetylase inhibitors
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
JP7451485B2 (ja) 癌の予防または治療に使用するための化合物
JP2020520378A (ja) アスコクロリン誘導体を用いた併用療法
CN102267923B (zh) 组蛋白去乙酰化酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131029